U.S. pharmaceutical giant Bristol-Myers Squibb has struck a strategic partnership and licensing deal with major Chinese drugmaker Hengrui Pharmaceuticals, in a deal that could worth more than $15 billion.
Source link
About The Author
Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-Up